Johnson & Johnson vs. Eli Lilly: Which Healthcare Giant's Stock Is a Better Buy for 2027?

The article compares two pharmaceutical giants for 2027 investment. Johnson & Johnson offers stability with a 6% revenue growth, lower P/E ratio of 42.59, and strong free cash flow of $19.7B, but faces patent expirations and litigation risks. Eli Lilly demonstrates explosive 44.7% revenue growth driven by GLP-1 drugs like Mounjaro and Zepbound, commanding a premium valuation (P/E 47.05), with significant future growth potential but concentrated revenue dependency.

11/11/2026, 3:00 PM • The Motley Fool

Johnson & Johnson Sees a Path to Double-Digit Growth by 2030. Is the Dividend King a Buy?

Johnson & Johnson is positioned to achieve double-digit sales growth by 2030 following its consumer health spinoff. Despite facing a major patent cliff with Stelara losing exclusivity in 2025, the company's new drug launches (Icotyde, Inlexzo, Lazcluze, Imaavy) with peak sales potential exceeding $5 billion each, combined with its robotic surgery device Ottava and strong dividend history as a Dividend King, make it an attractive investment for long-term income seekers.

11/11/2026, 2:57 PM • The Motley Fool

Global Injectables Market is Anticipated to Surpass USD 1 Trillion Mark by 2034 | DelveInsight

The global injectables market is projected to grow from USD 765 billion in 2025 to USD 1.6 trillion by 2034, with a CAGR of approximately 9%. Growth is driven by rising adoption of biologics, biosimilars, GLP-1 therapies, and advances in drug-delivery technologies like prefilled syringes and auto-injectors. North America leads with 39% market share, while Asia-Pacific represents the fastest-expanding region. Key developments include West Pharmaceutical Services' Dublin expansion and Fresenius Kabi's U.S. manufacturing collaboration.

11/11/2026, 1:00 PM • GlobeNewswire

Stocks Fell After the Midterms. History Says the Next 12 Months Could Be Very Different

U.S. stock markets declined following midterm elections due to voter opposition to data center expansion plans and concerns about AI regulation. However, historical data shows the S&P 500 has averaged ~15% returns in the 12 months following midterm elections since 1950. The article recommends staying calm, maintaining long-term positions, and considering investments in broad market index funds, undervalued stocks, and defensive healthcare stocks.

11/10/2026, 12:51 PM • The Motley Fool

1 Reliable ETF I'm Buying Forever, Even if the Stock Market Crashes

The author recommends the Vanguard S&P 500 ETF (VOO) as a reliable long-term investment despite current market volatility and crash concerns. VOO offers diversification across 500 large U.S. companies, a low 0.03% expense ratio, and has historically recovered from all 27 bear markets it has experienced, averaging 12.5% annual returns since 2010. The author suggests dollar-cost averaging to mitigate timing risk in uncertain market conditions.

11/10/2026, 12:00 PM • The Motley Fool

Peptide Therapeutics Market: Global Size, Share, Trends and Forecast to 2036 | Set to Reach $229.32 Billion as GLP-1, Oral Peptides, Radioligands, and Generics Fuel Growth

The global peptide therapeutics market is projected to grow from $112.20 billion in 2026 to $229.32 billion by 2036 at a 7.4% CAGR, driven by GLP-1 and incretin therapies, oral peptides, radioligands, and generic competition. Eli Lilly and Novo Nordisk lead the market with blockbuster incretin products, while emerging opportunities include oral macrocyclic peptides, radioligands, and generic semaglutide following patent expiry in major markets.

11/10/2026, 11:00 AM • GlobeNewswire

The Buffett Indicator Is Flashing Red. These 3 Dividend Stocks Could Be Safe Havens.

With the Buffett Indicator at 281% (signaling potential market overvaluation), the article recommends three Dividend King stocks as defensive investments: Target, Johnson & Johnson, and Coca-Cola. All three offer reliable dividend growth, strong financial fundamentals, and historical resilience, making them suitable safe havens during potential market downturns.

11/10/2026, 4:02 AM • The Motley Fool

Intuitive Surgical Placed 546 da Vinci Systems Last Quarter. Why Wall Street's Sell-Off Misses the Point.

Intuitive Surgical's stock fell despite strong quarterly results, but investors are overlooking the company's true business model. While da Vinci robot sales account for only 25% of revenue, the remaining 75% comes from services, instruments, and accessories for its installed base of 12,094 systems. With procedure volumes up 15% year-over-year and the surgical robotics market still in early adoption stages, the company's recurring revenue stream remains robust despite competitive pressures from Medtronic and Johnson & Johnson.

11/08/2026, 2:15 PM • The Motley Fool

Choosing Healthcare ETFs: Why IHE Outperforms IBB for Many Investors

The iShares U.S. Pharmaceuticals ETF (IHE) offers lower costs, higher dividend yield (1.4% vs 0.2%), and better 5-year returns (79% vs 38%) compared to the iShares Biotechnology ETF (IBB). IHE focuses on 53 established drugmakers with lower volatility, while IBB provides broader exposure to 243 biotech firms with higher risk. IHE may be preferable for income-focused investors, though IBB suits those seeking broader biotech sector exposure.

11/07/2026, 11:15 AM • The Motley Fool

The Healthcare ETF Showdown: Broad Global Health or Targeted Pharma Power?

Invesco Pharmaceuticals ETF (PJP) delivers higher returns (32.8% over one year, 10.7% CAGR since 2021) with concentrated U.S. pharma exposure but higher fees (0.58%), while iShares Global Healthcare ETF (IXJ) offers broader global diversification across 109 holdings, lower costs (0.38%), and higher dividend yield (1.3%), making it suitable for cost-conscious investors seeking diversified healthcare exposure.

11/07/2026, 9:15 AM • The Motley Fool

Breakfast News: Stocks That Let You Sleep at Night

The Motley Fool analysts recommend four steady stocks that historically move less than the market and can help investors stay confident during market downturns: Costco (strong membership model with 90% renewal rates), Realty Income (REIT with 50+ years of dividend growth), Mastercard (dominant payments network with consistent growth), and Johnson & Johnson (Dividend King with 64 consecutive years of dividend increases and AAA credit rating).

11/07/2026, 7:30 AM • The Motley Fool

If Stocks Tumble This Winter, History Says Investors Who Make This 1 Move Come Out Ahead

With stretched valuations and potential rate hikes ahead, stocks could decline this winter. However, historical data shows that the S&P 500 has recovered to new highs after all 38 corrections since 1950. The strategy of 'buying the dip' requires three ingredients: cash reserves, a list of quality stocks to purchase, and the discipline to invest when markets are fearful. Warren Buffett exemplified this approach during the 2008 financial crisis by purchasing stocks that subsequently quintupled.

11/07/2026, 4:44 AM • The Motley Fool

Hims & Hers Health vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy for 2027?

The article compares two healthcare disruptors: Hims & Hers Health, a high-growth telehealth platform with 59% revenue growth but facing regulatory scrutiny, and Intuitive Surgical, a dominant medical robotics leader with strong profitability and a 12% increase in installed systems. While both stocks declined in 2026, the author recommends Intuitive Surgical for its stronger competitive moat and market position, despite both being considered speculative investments.

11/06/2026, 10:05 PM • The Motley Fool

Monte Rosa Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates

Monte Rosa Therapeutics announced positive Phase 1 results for MRT-8102, showing significant NEK7 degradation and reduction in cardiovascular disease markers with safety comparable to placebo. The company plans to initiate three Phase 2 studies in gout, coronary artery disease, and hidradenitis suppurativa. Additionally, Novartis initiated Phase 2 studies of partnered program MRT-6160 in Sjögren's disease and psoriatic arthritis, triggering $87.5 million in milestone payments. The company maintains a strong cash position of $582.6 million, expected to support operations into 2029.

11/05/2026, 7:00 AM • GlobeNewswire

T-Therapeutics announces oversubscribed $133 million Series B financing to achieve clinical proof-of-concept for first-in-class TCR bispecific therapies in cancer and autoimmune disease

T-Therapeutics closed a $133 million Series B funding round co-led by Advent Life Sciences and British Business Bank to advance clinical development of first-in-class TCR-CD3 bispecific therapies for cancer and autoimmune diseases. The company appointed Dr. Kirsty Crame as Chief Development Officer and plans to generate clinical proof-of-concept data for two lead programmes leveraging its proprietary OpTiMus platform.

11/05/2026, 2:00 AM • GlobeNewswire